Isoray Declares Outcomes of Fiscal 2023 Annual Assembly of Stockholders
Stockholders Approve Proposal One Clearing Method for Consummation of Merger
RICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE AMERICAN: ISR), a medical know-how firm and innovator in seed brachytherapy powering increasing remedy choices all through the physique, in the present day introduced the outcomes of its adjourned Fiscal 2023 Annual Assembly of Stockholders which was held on January 27, 2023.
The stockholders accepted Proposal One which amends the Firm’s Certificates of Incorporation to extend the whole variety of approved shares of Frequent Inventory to 750,000,000 shares. Proposal One, which required an affirmative vote of a majority of the excellent widespread inventory for passage, acquired 71,844,322 share votes in favor of the proposal which represents 50.55% of the whole shares excellent. The passage of Proposal One permits the Firm to proceed with the proposed merger with Viewpoint Molecular Focusing on, Inc. The Firm anticipates finishing the merger within the close to future.
Isoray, Inc. is a medical know-how firm pioneering superior remedy purposes and units to ship focused inside radiation remedies for cancers all through the physique. Isoray, Inc., by way of its subsidiary, Isoray Medical, Inc., is the only producer of Cesium-131 brachytherapy seeds. Study extra about this progressive Richland, Washington firm and discover the numerous advantages and makes use of of Cesium-131 by visiting www.isoray.com. Observe us on LinkedIn and Twitter.
Protected Harbor Assertion
Statements on this information launch about Isoray’s future expectations, together with: the timing of the completion of the proposed merger with Viewpoint Molecular Focusing on, Inc., and all different statements on this launch, aside from historic information, are “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act of 1995 (“PSLRA”). This assertion is included for the specific goal of availing Isoray, Inc. of the protections of the secure harbor provisions of the PSLRA. You will need to word that precise outcomes and supreme company actions may differ materially from these in such forward-looking statements primarily based on such components because the timing and shutting of the proposed merger with Viewpoint Molecular Focusing on, Inc., together with whether or not all closing situations are glad or waived, whether or not the merger is accomplished and, in that case, whether or not the anticipated advantages of the merger are realized. Except required to take action by legislation, we undertake no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
CONTACT: Contacts Investor Relations: Mark Levin (501) 255-1910 Media and Public Relations: Sharon Schultz (302) 539-3747